YD Life Science   Report issue

For profit Phase 2
Founded: Seongnam Korea, Republic of (2008)

Organization Overview

First Clinical Trial
2017
NCT03635814
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Se Hee Han | YD Global Life Science Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

imatinib (gleevec) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Edema (Phase 2)

Macular Edema (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1